Keywords: new, data, ligand, targretin, ontak, adding, pharmaceuticals
New data on Ligand's Targretin, Ontak
Article | 27 May 2002
Adding Ligand Pharmaceuticals' Targretin (bexarotene) to standardchemotherapy (paclitaxel/carboplatin) can enhance the activity of non-small cell lung cancer treatment and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
